Comparing 3 approaches for endometrial cancer

Exclusion

• −Have a history of allergies, hypersensitivities, or intolerance to study treatments (investigational medicinal products and auxiliary medicinal product) including any excipients thereof or to other monoclonal antibodies. Participants who have successfully undergone a desensitization process and are able to tolerate the drug are eligible.
• −Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior the first dose of study treatment.
• −Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse eventsAdverse eventAny medical problem that happens during a study, whether or not the treatment caused it.Read more →.
• −Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, or peritoneal shunt within 2 weeks prior to the first dose of study treatment.
• −Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screeningScreeningThe checks done before joining, to see whether a study fits.Read more →.
• −Participants with prior use of immunosuppressive medication within 14 days prior to the first dose of study treatment, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses of less than 10 mg/day of prednisone or equivalent, and topical corticosteroids. Participants receiving corticosteroids may continue if the dose is stable upon giving main informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →.
• −Have uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to the first dose of study treatment.
• −Have unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than alopecia, fatigue, or endocrinopathies that are well controlled) not yet resolved to Grade ≤1 or baselineBaselineYour starting measurements, taken before treatment begins.Read more →.
• −Had prior treatment with topoisomerase I inhibitors, including ADCs.
• −Have left ventricular ejection fraction \<55% by either echocardiography or multiple-gated acquisition within 28 days prior to the first dose of study treatment. This includes participants with tissue doppler E/e' ratio \>15.
• −NOTE: Other protocolProtocolThe detailed plan a study must follow.Read more → defined InclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →/Exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → apply.
• −Are pregnant or breastfeeding or are planning pregnancy during the study or within 7 months after the last dose of study treatment.
• −Are ineligible for all options in the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →'s choice of chemotherapy armArmOne of the groups in a study, each receiving something different.Read more →, per local prescribing information and institutional guidelines (applicable to CohortCohortA group of participants sharing a characteristic, followed together.Read more → 1 only).
• −Have a lung-specific intercurrent clinically significant illness including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months prior to the first dose of study treatment, severe asthma, chronic obstructive pulmonary disorder with moderate acute exacerbations, restrictive lung disease, pulmonary fibrosis, radiation pneumonitis, significant pleural effusion etc.), or any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy (complete).